Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | September 03, 2013

Recent rulings on opposed motions to stay pending reexam and motions to stay pending Inter Partes Review in the Eastern and Southern Districts of Texas

Blog | August 27, 2013

Federal Rules of Civil Procedure proposed amendments

Q&A | August 19, 2013

Q&A with Juanita Brooks: Becoming a Rainmaker

Blog | August 06, 2013

Congress focuses on abusive patent litigation

Blog | June 22, 2013

FTC announces NPE investigation, possible antitrust action

Blog | June 06, 2013

NPE activity still rising, but Obama executive order attempts to curb that

Blog | June 05, 2013

NPE activity still rising, but Obama executive order attempts to curb that

Q&A | March 12, 2013

Q&A With Fish's Michael McKeon

Article | March 13, 2012

Biosimilars vs. Generics - Major Differences in the Regulatory Model

Article | October 21, 2011

Is It Time for FDA to Revise Its Orange Book Rules to Deal with Skinny Labeled Generic Drugs?

Q&A | June 13, 2011

Q&A with Juanita Brooks: National Law Journal Spotlight

Article | December 09, 2010

Skinny Labeling and the Inducement of Patent Infringement